BGC201531

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 531569

CAS#: 1186532-61-5

Description: BGC201531, also known as GTPL3380 and AP-1531, is a EP4 antagonist for the treatment of acute migraine.


Price and Availability

Size
Price

Size
Price

Size
Price

BGC201531 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 531569
Name: BGC201531
CAS#: 1186532-61-5
Chemical Formula: C26H28N2O6S
Exact Mass: 496.1668
Molecular Weight: 496.58
Elemental Analysis: C, 62.89; H, 5.68; N, 5.64; O, 19.33; S, 6.46


Synonym: BGC201531; BGC-201531; BGC 201531; GTPL3380;GTPL-3380; GTPL 3380; AP-1531; AP1531; AP1531;

IUPAC/Chemical Name: 4-[4-(5-methoxypyridin-2-yl)phenoxymethyl]-5-methyl-N-[(2-methylbenzene)sulfonyl]oxolane-2-carboxamide

InChi Key: BGXAOTTWXYPIQN-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H28N2O6S/c1-17-6-4-5-7-25(17)35(30,31)28-26(29)24-14-20(18(2)34-24)16-33-21-10-8-19(9-11-21)23-13-12-22(32-3)15-27-23/h4-13,15,18,20,24H,14,16H2,1-3H3,(H,28,29)

SMILES Code: O=C(NS(=O)(C1=CC=CC=C1C)=O)C2OC(C(C2)COC3=CC=C(C=C3)C4=NC=C(C=C4)OC)C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Antonova M, Wienecke T, Maubach K, Thomas E, Olesen J, Ashina M. The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache. J Headache Pain. 2011 Oct;12(5):551-9. doi: 10.1007/s10194-011-0358-9. Epub 2011 Jun 17. PubMed PMID: 21681585; PubMed Central PMCID: PMC3173651.

2: Maubach KA, Davis RJ, Clark DE, Fenton G, Lockey PM, Clark KL, Oxford AW, Hagan RM, Routledge C, Coleman RA. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 Jan;156(2):316-27. doi: 10.1111/j.1476-5381.2009.00027.x. Epub 2009 Jan 19. PubMed PMID: 19154437; PubMed Central PMCID: PMC2697835.

3: Antonova M. Prostaglandins and prostaglandin receptor antagonism in migraine. Dan Med J. 2013 May;60(5):B4635. Review. PubMed PMID: 23673269.